Breast Cancer
Breast cancer cryoablation, which destroys tumor cells by exposing them to subfreezing temperatures, appears to be an effective alternative to surgery for women aged >60 years with low-risk, early-stage breast cancer, according to findings from the ICE3 trial. Read More ›
Pembrolizumab (Keytruda) plus chemotherapy improved progression-free survival (PFS) compared with chemotherapy alone as first-line treatment of metastatic triple-negative breast cancer (TNBC), according to the results of KEYNOTE-355. Read More ›
The addition of the cyclin-dependent kinase (CDK)4/6 inhibitor abemaciclib (Verzenio) to standard endocrine therapy reduced the risk for invasive disease recurrence or death compared with endocrine therapy alone by almost 30% in patients with high-risk, hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative, early-stage breast cancer. Read More ›
We have taken part in a unique evolution in medicine, as we have modified our clinical processes and practices, clinical trials and research programs, and educational vehicles because of the COVID-19 pandemic in 2020. Read More ›
Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib. Read More ›
In this real-world retrospective study, more patients in the ribociclib cohort compared with palbociclib and abemaciclib maintained starting doses and fewer patients decreased to 50% of the starting dose. Read More ›
In addition to the significant benefit observed in the MONARCH 2 study across first- and second-line treatment, marked effects were observed in patients with less encouraging prognostic indicators. Read More ›
Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative, endocrine-sensitive, advanced breast cancer. Read More ›
Across the MONALEESA-2, -3, and -7 clinical trials, first-line treatment with endocrine therapy and ribociclib mitigated negative effects on quality of life, global health scores, pain, and emotional functioning. Read More ›
While progression-free survival was similar, overall survival was better in CDK4/6 inhibitor combinations as first-line therapy followed by everolimus combinations and chemotherapy. Read More ›